SPERO THERAPEUTICS INC (SPRO)       1.83  -0.06 (-3.17%)

1.83  -0.06 (-3.17%)

US84833T1034 - Common Stock - After market: 1.89 +0.06 (+3.28%)

SPERO THERAPEUTICS INC1.83

NASDAQ:SPRO (12/6/2022, 7:04:35 PM)-0.06 (-3.17%)

After market: 1.89 +0.06 (+3.28%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-14 2022-11-14/amc Earnings (Next) 03-29 2023-03-29
Ins Owners 1.77% Inst Owners 38.4%
Market Cap 94.75M Shares 51.78M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 80
IPO 11-02 2017-11-02

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

SPRO Daily chart

Company Profile

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company is headquartered in Cambridge, Massachusetts and currently employs 41 full-time employees. The company went IPO on 2017-11-02. The firm is focused on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant (MDR) bacterial infections, and rare diseases where there is unmet medical and patient need. Its lead product candidate, tebipenem pivoxil hydrobromide (tebipenem HBr) is designed to be the first oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections (cUTIs), including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options. Its pipeline also includes SPR720 and SPR206. SPR720 is designed to be the first oral treatment for non-tuberculous mycobacterial (NTM) infection. SPR206 is a direct acting intravenous (IV) administered polymyxin analogue developed from its potentiator platform to treat MDR Gram-negative bacterial infections within the hospital.

Company Info

SPERO THERAPEUTICS INC

675 Massachusetts Ave Ste 14

Cambridge MASSACHUSETTS 02139

P: 18572421600.0

CEO: Ankit Mahadevia

Employees: 41

Website: https://sperotherapeutics.com/

SPRO News

News Image15 days ago - Spero Therapeutics, Inc.Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference

CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical...

News Image22 days ago - Spero Therapeutics, Inc.Spero Therapeutics Announces Third Quarter 2022 Operating Results and Provides Business Update

Entered into and closed exclusive license agreement with GSK for tebipenem HBr, pursuant to which Spero receives $66 million upfront, and a $9 million...

News Imagea month ago - Spero Therapeutics, Inc.Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr

Pursuant to the agreement, Spero will be receiving a $66 million upfront payment, received a $9 million direct equity investment in shares of Spero common...

News Imagea month ago - Spero Therapeutics, Inc.Spero Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company,...

News Image2 months ago - Spero Therapeutics, Inc.Spero Therapeutics to Present Data at IDWeek 2022

CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company,...

News Image2 months ago - Spero Therapeutics, Inc.Spero Therapeutics to Host Virtual R&D Event on Non-Tuberculous Mycobacterial Pulmonary Disease and the SPR720 Program

Event is taking place on Thursday, October 6th at 11:30 a.m. ET Event will feature a presentation by key opinion leader, Kevin L. Winthrop, MD, MPH...

SPRO Twits

Here you can normally see the latest stock twits on SPRO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example